North America Monoclonal Antibodies Market to Grow at a CAGR of 12.0% to reach US$ 1,20,713.2 million from 2021 to 2028

North America Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), End-User (Hospitals, Research Institutes, and Others)

  • Report Code : TIPRE00027987
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 169
Buy Now

The North America monoclonal antibodies market is expected to reach US$ 1,20,713.2 million by 2028 from US$ 54,629.4 million in 2021. The market is estimated to grow at a CAGR of 12.0% from 2021–2028.

According to the International AIDS Vaccine Initiative (IAVI) report, the development of mABs is one of the fastest-growing segments of biomedical research. For records, more than 50 mABs were licensed in the last six years, and in 2019, seven of the ten best-selling novel drugs for cancer and autoimmune diseases were mABs. Further, with the growing number of non-communicable and infectious diseases, for which mABs are or might prove effective treatment, there is certainly an accelerating demand for such products. For example, mABs sales are predominant in the US. As the percentage of mABs in the development pipeline increases, more and more mABs will enter the market, and the disparity in access between high-income countries and the rest of the world will worsen. Furthermore, a few combinations of mABs are also being developed to address many diseases, including chronic infections and cancer. On the other hand, several counties are taking strong initiatives to shorten the regulatory process for mABs effective for treating chronic diseases. For records, in early 2019, the CFDA approved three mABs from domestic developers and ten mABs from multinational pharmaceutical companies. Such factors are stimulating the uptake of mABs, aiding the market significantly.Favorable government regulations in North America regional market authorizes monoclonal antibodies during the onset of the pandemic. For instance, in December 2021, The US Food and Drug Administration (FDA) announced Emergency Use Authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) intended for pre-exposure prophylaxis of COVID-19 for certain adults and pediatric individuals. As monoclonal antibodies are laboratory manufactured proteins involved in mimicking the immune system's ability to fight off harmful pathogens such as viruses. Therefore, "Tixagevimab" and "cilgavimab" are long-acting monoclonal antibodies particularly directed for spike protein of SARS-CoV-2. Apart from that, favorable funding for development of biologics further enhanced the market growth for monoclonal antibodies during the onset of pandemic in North America regional market. For example, the US International Development Finance Corporation (DFC) announced furnishing of US$50 million to Biological E Limited for increasing COVID-19 vaccine manufacturing capacity. Also, favorable policy relating to product approvals for biologics by the FDA positively impacts the market growth.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the monoclonal antibodies market. The North America monoclonal antibodies market is expected to grow at a good CAGR during the forecast period.


North America Monoclonal Antibodies Market Revenue and Forecast to 2028 (US$ Million)

North America Monoclonal Antibodies Market Revenue and Forecast to 2028 (US$ Million)
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

North America Monoclonal Antibodies Market Segmentation    

By Source

  • Human
  • Humanized
  • Chimeric
  • Murine

By Production Method

  • In-Vitro
  • In-Vivo

By Indication

  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Inflammatory Diseases
  • Microbial Diseases
  • Others

By Application

  • Therapeutic Applications
  • Diagnostic Applications
  • Research Applications

By End-User

  • Hospitals
  • Research Institutes
  • Others

By Country

  • North America
  • US
  • Canada
  • Mexico

Companies Mentioned

  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Amgen Inc
  • DAIICHI SANKYO COMPANY, LIMITED
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
  • Eli Lilly and Company
  • Bayer AG
  • Bristol-Myers Squibb Company
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

  1. Novartis AG
  2. Pfizer Inc.
  3. GlaxoSmithKline plc.
  4. Amgen Inc
  5. DAIICHI SANKYO COMPANY, LIMITED
  6. F. Hoffmann-La Roche Ltd.
  7. AstraZeneca
  8. Eli Lilly and Company
  9. Bayer AG
  10. Bristol-Myers Squibb Company

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to North America Monoclonal Antibodies Market